Literature DB >> 4285216

Immunological studies of human gliomas.

M S Mahaley, E D Day.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1965        PMID: 4285216     DOI: 10.3171/jns.1965.23.4.0363

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


× No keyword cloud information.
  8 in total

Review 1.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

2.  Membrne alterations in human glioblastoma.

Authors:  W Lubitz; A Reichert; G Birkmayer
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

Review 3.  Immunobiologic aspects of the brain and human gliomas. A review.

Authors:  C J Wikstrand; D D Bigner
Journal:  Am J Pathol       Date:  1980-02       Impact factor: 4.307

4.  Heterologous antibodies in human and rat's glioblastoma.

Authors:  J E Roda; F Villarejo; J Heredero; S Obrador
Journal:  Acta Neurochir (Wien)       Date:  1976       Impact factor: 2.216

5.  Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.

Authors:  D D Bigner; M Brown; R E Coleman; A H Friedman; H S Friedman; R E McLendon; S H Bigner; X G Zhao; C J Wikstrand; C N Pegram
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 6.  Current status of cancer imaging with radiolabeled antibodies.

Authors:  D M Goldenberg
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

7.  An attempt to detect cell surface antigens in cultured human brain tumors by mixed hemadsorption test. First report.

Authors:  E Miyake; K Kitamura; K Nomoto; K Takeya
Journal:  Acta Neuropathol       Date:  1977-01-31       Impact factor: 17.088

8.  Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy.

Authors:  H J Bloom; M J Peckham; A E Richardson; P A Alexander; P M Payne
Journal:  Br J Cancer       Date:  1973-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.